Fibrates has 33 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 11 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ezetimibe, Atorvastatin Calcium, Fluvastatin Sodium. Patients taking Fibrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 33
- Contraindicated
- 1
- Major
- 11
- Moderate
- 21
Contraindicated (1)
- Fibrates + Ezetimibe— Co-administration of ezetimibe with fibrates other than fenofibrate is not recommended until adequately studied.
Major (11)
- Fibrates + Atorvastatin Calcium— Fibric acid derivatives increase risk of myopathy/rhabdomyolysis. Caution should be used when prescribing together.
- Fibrates + Fluvastatin Sodium— Fibrates may cause myopathy when used alone; concomitant use with fluvastatin increases risk of myopathy and rhabdomyoly…
- Fibrates + Gentamicin Sulfate— Neuromuscular blockade and respiratory paralysis possible with massive transfusions during aminoglycoside therapy.
- Fibrates + Insulin Degludec— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Fibrates + Insulin Glargine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Fibrates + Insulin Glargine-Yfgn— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Fibrates + Lovastatin— Lipid-lowering drugs that increase risk of myopathy when given with lovastatin.
- Fibrates + Pitavastatin— Fibrates may cause myopathy alone and increase risk of myopathy and rhabdomyolysis when combined with pitavastatin. Risk…
- Fibrates + Pitavastatin Calcium— Fibrates increase the risk of myopathy and rhabdomyolysis when used concomitantly with pitavastatin. Benefit-risk assess…
- Fibrates + Pravastatin Sodium— Risk of myopathy and rhabdomyolysis is increased with concomitant use. Monitor for signs and symptoms of myopathy during…
- Fibrates + Rosuvastatin Calcium— Concomitant use with fibrates increases risk of adverse skeletal muscle effects including myopathy. Caution should be us…
Moderate (21)
- Fibrates + Bempedoic Acid— Concomitant use may result in increased triglycerides and decreased HDL-C. Monitor triglycerides and HDL-C levels; disco…
- Fibrates + Bempedoic Acid And Ezetimibe— Concomitant use with bempedoic acid resulted in increased triglycerides and decreased HDL-C in some patients. Monitor li…
- Fibrates + Colchicine— Other lipid-lowering drugs that may interact with colchicine. Monitor patients during coadministration.
- Fibrates + Glimepiride— May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
- Fibrates + Glipizide— May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.
- Fibrates + Insulin Aspart Injection— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Fibrates + Insulin Aspart-Szjj— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Fibrates + Insulin Degludec And Liraglutide— May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
- Fibrates + Insulin Detemir— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Fibrates + Insulin Glargine And Lixisenatide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
- Fibrates + Insulin Glargine-Aglr— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
- Fibrates + Insulin Glulisine— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Fibrates + Insulin Human— May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
- Fibrates + Insulin Lispro— May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
- Fibrates + Insulin Lispro-Aabc— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Fibrates + Magnesium Chloride, Dextrose Anhydrous, Lactic Acid, Sodium Chloride, Sodium Bicarbonate, And Potassium Chloride— When used as an anticoagulant, citrate contributes to overall buffer load and can reduce plasma calcium levels. Appropri…
- Fibrates + Pitavastatin Magnesium— Fibrates may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use with…
- Fibrates + Pramlintide Acetate— May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.
- Fibrates + Rosuvastatin— Use with fibrates increases risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuva…
- Fibrates + Simvastatin— Caution should be used when prescribing other fibrate products with simvastatin; increases risk of adverse skeletal musc…
- Fibrates + Sodium Chloride, Sodium Gluconate, Sodium Acetate, Potassium Chloride And Magnesium Chloride— Solutions containing calcium in excess of normal plasma concentration may enhance clotting on contact with citrated bloo…